HC Wainwright Reaffirms “Buy” Rating for Milestone Pharmaceuticals (NASDAQ:MIST)

Milestone Pharmaceuticals (NASDAQ:MIST)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued on Monday,Benzinga reports. They currently have a $25.00 price objective on the stock. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ FY2029 earnings at $1.86 EPS.

Milestone Pharmaceuticals Stock Performance

MIST stock opened at $1.98 on Monday. The company has a 50 day moving average price of $1.97 and a 200 day moving average price of $1.67. Milestone Pharmaceuticals has a fifty-two week low of $1.12 and a fifty-two week high of $2.75. The company has a debt-to-equity ratio of 2.18, a current ratio of 15.40 and a quick ratio of 15.40. The stock has a market capitalization of $105.59 million, a PE ratio of -2.44 and a beta of 1.78.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its earnings results on Tuesday, November 12th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. Analysts forecast that Milestone Pharmaceuticals will post -0.62 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Valeo Financial Advisors LLC lifted its holdings in Milestone Pharmaceuticals by 100.0% in the third quarter. Valeo Financial Advisors LLC now owns 20,000 shares of the company’s stock valued at $30,000 after buying an additional 10,000 shares during the period. PVG Asset Management Corp bought a new stake in shares of Milestone Pharmaceuticals during the 3rd quarter valued at $46,000. Atria Investments Inc lifted its stake in shares of Milestone Pharmaceuticals by 44.4% in the 3rd quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock valued at $61,000 after purchasing an additional 12,430 shares during the period. Finally, BML Capital Management LLC boosted its position in shares of Milestone Pharmaceuticals by 3.0% in the 3rd quarter. BML Capital Management LLC now owns 1,136,091 shares of the company’s stock worth $1,727,000 after purchasing an additional 33,196 shares during the last quarter. Institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.